NCT07096778 - Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2029

Conditions

Multiple Myeloma RefractoryMultiple Myeloma in Relapse

Interventions

DRUG

Inobrodib

40 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.

DRUG

Pomalidomide

4 mg orally once daily on Day 1 to 21 of each 28-day cycle

DRUG

Dexamethasone

40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle

Trial Locations (1)

Royal Marsden NHS Foundation Trust, Sutton